- Home
- FTS vs ONC Comparison
FTS vs ONC Comparison
Compare FTS & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTS | ONC |
|---|---|---|
| Founded | 1885 | 2010 |
| Country | Canada | Switzerland |
| Employees | 9900 | 12000 |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.0B | 31.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FTS | ONC |
|---|---|---|
| Price | $55.90 | $270.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $67.00 | ★ $385.10 |
| AVG Volume (30 Days) | ★ 511.9K | 212.9K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.05 | $723.76 |
| Revenue Next Year | $5.32 | $15.04 |
| P/E Ratio | ★ $22.72 | $614.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $46.46 | $239.25 |
| 52 Week High | $58.78 | $385.22 |
Technical Indicators
Market Signals| Indicator | FTS | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 49.12 | 31.33 |
| Support Level | $54.93 | N/A |
| Resistance Level | $57.67 | $323.73 |
| Average True Range (ATR) | 0.85 | 7.31 |
| MACD | -0.06 | -3.19 |
| Stochastic Oscillator | 55.91 | 0.51 |
Price Performance
Historical ComparisonAbout FTS Fortis Inc.
Fortis owns and operates eight utility transmission and distribution subsidiaries in Canada and the United States, serving 3.5 million electricity and gas customers. The company has smaller stakes in electricity generation and several Caribbean utilities. Subsidiary ITC operates electric transmission in seven US states, with more than 16,000 miles of high-voltage transmission lines in operation.
About ONC BeiGene Ltd. American Depositary Shares
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.